SCHEMBL1906531

SCHEMBL1906531

CCOC(=O)c1cnc2nc(C(=O)O)ccc2c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 4/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
ATM Q13315 1/20 0.44
RAB9A P51151 4/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 2/20 0.44
MEN1 O00255 1/20 0.44
TP53 P04637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 3/20 0.41
POLB P06746 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1905334 0.85 KMT2A (0.49) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL9874630 0.83 KMT2A (0.50) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL8327448 0.83 NPC1 (0.44) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL23145042 0.82 KMT2A (0.44) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL29843352 0.82 KMT2A (0.44) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL1902321 0.82 KDM4E (0.44) ALDH1A1MAPTLMNARAB9AKMT2A
SCHEMBL8568056 0.80 KDM4E (0.49) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL11331742 0.79 MAPK8 (0.43) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL8558995 0.78 DPP4 (0.46) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL2961438 0.77 ELANE (0.49) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 ALDH1A1 4287/4885SMN1; SMN2 1178/4885MAPT 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.